ArticleBMC cancer2026

Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2

Alessandro Rizzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.